The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Abstract
The study describes the clinical and pathological findings in 12 patients with relapsing and remitting multiple sclerosis, who died during or shortly after the onset of a relapse. Pathological changes not previously associated with the formation of new symptomatic lesions were observed in seven cases, namely, extensive oligodendrocyte apoptosis and microglial activation in myelinated tissue containing few or no lymphocytes or myelin phagocytes. No current laboratory model of multiple sclerosis, in particular, experimental allergic encephalomyelitis, is known with these features, which raises the possibility of some novel process underlying new lesion formation in multiple sclerosis. Ann Neurol 2004;55:000–000
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
Handbook of clinical neurology
(1986) · Journal of Neuroimmunology · doi:10.1016/0165-5728(86)90030-5 · Cited by 1,849
Four deaths and a funeral: from caspases to alternative mechanisms
Leist, M., & Jäättelä, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085008 · Cited by 1,587
Corpse clearance defines the meaning of cell death
Savill, J., & Fadok, V. (2000) · Nature · doi:10.1038/35037722 · Cited by 1,547
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
Tumor necrosis factor identified in multiple sclerosis brain.
Hofman, F. M., Hinton, D. R., Johnson, K., & Merrill, J. E. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.2.607 · Cited by 801
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide.
Merrill, J. E., Ignarro, L. J., Sherman, M. P., Melinek, J., & Lane, T. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.2132 · Cited by 781
Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy
Lassmann, H., Brück, W., & Lucchinetti, C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(00)01909-2 · Cited by 627
Cited by
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Lassmann, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028936 · Cited by 937
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Oxidative damage in multiple sclerosis lesions
Haider, L., Fischer, M. T., Frischer, J. M., Bauer, J., Hoftberger, R., Botond, G., Esterbauer, H., Binder, C. J., Witztum, J. L., & Lassmann, H. (2011) · Brain · doi:10.1093/brain/awr128 · Cited by 753
TLR signaling tailors innate immune responses in human microglia and astrocytes
Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., Shapiro, A., & Antel, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4320 · Cited by 734
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
“1A and B); (ii) initial lesions, defined as ‘pre-phagocytic’ lesions by Barnett and Prineas (2004) (Fig.”
BackgroundInfluentialAn updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692
“Histopathological studies analyzing tissue samples from patients who died either shortly after a relapse or due to acute MS (so called Marburg’s type of MS) observed areas of microglial activation and dying oligodendrocytes [4], or microglia activation, edema, and low numbers of APP positive axons [39].”
BackgroundMiller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Role of the innate and adaptive immune responses in the course of multiple sclerosis
Hemmer, B., Kerschensteiner, M., & Korn, T. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70305-9 · Cited by 584
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Machado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
Multiple sclerosis: experimental models and reality
Lassmann, H., & Bradl, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1631-4 · Cited by 525
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
The cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481
“white matter [9, 55], recent histopathological studies have convincingly shown that grey matter regions are also massively affected [32, 55].”
BackgroundWill the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Epstein–Barr virus and multiple sclerosis
Soldan, S. S., & Lieberman, P. M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00770-5 · Cited by 467
Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Development, Damage, and Repair
Domingues, H. S., Portugal, C. C., Socodato, R., & Relvas, J. B. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00071 · Cited by 432
Cooperative, O. B. O. T. N., Sati, P., Oh, J., Constable, R. T., Evangelou, N., Guttmann, C. R. G., Henry, R. G., Klawiter, E. C., Mainero, C., Massacesi, L., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.166 · Cited by 426
Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits
Kapoor, B., Kapoor, D., Gautam, S., Singh, R., & Bhardwaj, S. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00363-3 · Cited by 418
Veerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
bHLH Transcription Factor Olig1 Is Required to Repair Demyelinated Lesions in the CNS
Arnett, H. A., Fancy, S. P. J., Alberta, J. A., Zhao, C., Plant, S. R., Kaing, S., Raine, C. S., Rowitch, D. H., Franklin, R. J. M., & Stiles, C. D. (2004) · Science · doi:10.1126/science.1103709 · Cited by 416
Exploring the origins of grey matter damage in multiple sclerosis
Calabrese, M., Magliozzi, R., Ciccarelli, O., Geurts, J. J. G., Reynolds, R., & Martin, R. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3900 · Cited by 414
Mitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406
“Mitochondrial defects in acute multiple sclerosis lesions Don Mahad,1 Iryna Ziabreva,1Hans Lassmann2 and DouglasTurnbull1 1The Mitochondrial Research Group, University of Newcastle uponTyne, UK and 2Centre for Brain Research, Medical University of Vienna, Austria Correspondence to: Prof. Dr Hans Lassmann, Center for B…”
BackgroundInfluentialPathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions
Henderson, A. P. D., Barnett, M. H., Parratt, J. D. E., & Prineas, J. W. (2009) · Annals of Neurology · doi:10.1002/ana.21800 · Cited by 387
Self-citationAxonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes
Kassmann, C. M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., Natt, O., Michaelis, T., Prinz, M., Frahm, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2070 · Cited by 357
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
“They have been found prevalently around active lesions [22] and they have been associated with axons undergoing Wallerian degeneration [2, 22, 41].”
Homogeneity of active demyelinating lesions in established multiple sclerosis
Breij, E. C. W., Brink, B. P., Veerhuis, R., van den Berg, C., Vloet, R., Yan, R., Dijkstra, C. D., van der Valk, P., & Bö, L. (2008) · Annals of Neurology · doi:10.1002/ana.21311 · Cited by 353
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
The cuprizone model for demyelination
Torkildsen, Ø., Brunborg, L. A., Myhr, K.-M., & Bø, L. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01036.x · Cited by 346
Wilms, H., Sievers, J., Rickert, U., Rostami-Yazdi, M., Mrowietz, U., & Lucius, R. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-30 · Cited by 344
Myelin‐associated glycoprotein (MAG): past, present and beyond
Quarles, R. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04319.x · Cited by 326
Oxidative stress in multiple sclerosis: Central and peripheral mode of action
Ohl, K., Tenbrock, K., & Kipp, M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.010 · Cited by 317
Disease-specific molecular events in cortical multiple sclerosis lesions
Fischer, M. T., Wimmer, I., Höftberger, R., Gerlach, S., Haider, L., Zrzavy, T., Hametner, S., Mahad, D., Binder, C. J., Krumbholz, M., et al. (2013) · Brain · doi:10.1093/brain/awt110 · Cited by 311
“In line with previous studies, apoptosis in multiple sclerosis lesions was not associated with caspase 3 activation (Barnett and Prineas, 2004), but with the liberation of apoptosis inducing factor from mitochondria and its nuclear translocation (Veto et al., 2010).”
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Infectious causes of multiple sclerosis
Giovannoni, G., Cutter, G. R., Lunemann, J., Martin, R., Münz, C., Sriram, S., Steiner, I., Hammerschlag, M. R., & Gaydos, C. A. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70577-4 · Cited by 295
The molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 294
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Marik, C., Felts, P. A., Bauer, J., Lassmann, H., & Smith, K. J. (2007) · Brain · doi:10.1093/brain/awm236 · Cited by 292
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M.-C., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 285
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
Neuroprotection and repair in multiple sclerosis
Franklin, R. J. M., ffrench-Constant, C., Edgar, J. M., & Smith, K. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.200 · Cited by 278
Remyelination in Experimental Models of Toxin-Induced Demyelination
Blakemore, W. F., & Franklin, R. J. M. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-73677-6_8 · Cited by 275
“That said, even this straightforward distinction may be less clear than previously thought, since some forms of MS may have more in common with toxin-induced demyelination [ 7 ], while the immune system (T cells) has a significant involvement in some toxininduced demyelination (specifically that following lysolecithin…”
BackgroundNeuroinflammation across neurological diseases
Shi, F.-D., & Yong, V. W. (2025) · Science · doi:10.1126/science.adx0043 · Cited by 274
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis
Sriram, S., & Steiner, I. (2005) · Annals of Neurology · doi:10.1002/ana.20743 · Cited by 264
Moscarello, M. A., Mastronardi, F. G., & Wood, D. D. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9144-5 · Cited by 264
Pathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
The Role of Astrocytes in Multiple Sclerosis Progression
Correale, J., & Farez, M. F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00180 · Cited by 261
Villar, L. M., Sádaba, M. C., Roldán, E., Masjuan, J., González-Porqué, P., Villarrubia, N., Espiño, M., García-Trujillo, J. A., Bootello, A., & Álvarez-Cermeño, J. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522833 · Cited by 259
Harauz, G., Ishiyama, N., Hill, C. M. D., Bates, I. R., Libich, D. S., & Farès, C. (2004) · Micron · doi:10.1016/j.micron.2004.04.005 · Cited by 256
Immunopathogenesis and immunotherapy of multiple sclerosis
Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., & Hartung, H.-P. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0154 · Cited by 254
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis
Teunissen, C. E., Dijkstra, C., & Polman, C. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00964-0 · Cited by 252
Lopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
Microglial Recruitment, Activation, and Proliferation in Response to Primary Demyelination
Remington, L. T., Babcock, A. A., Zehntner, S. P., & Owens, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060783 · Cited by 234
Zirngibl, M., Assinck, P., Sizov, A., Caprariello, A. V., & Plemel, J. R. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00538-8 · Cited by 270
Multiple sclerosis animal models: a clinical and histopathological perspective
Kipp, M., Nyamoya, S., Hochstrasser, T., & Amor, S. (2017) · Brain Pathology · doi:10.1111/bpa.12454 · Cited by 226
Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function
Spiteri, A. G., Wishart, C. L., Pamphlett, R., Locatelli, G., & King, N. J. C. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02384-2 · Cited by 244
“Other groups have instead used diphtheria toxin-induced death of oligodendrocytes to mimic the formation of lesions in some early MS cases, showing oligodendrocyte apoptosis in the absence of immune cell infiltration [17, 202, 313].”
Voß, E. V., Škuljec, J., Gudi, V., Skripuletz, T., Pul, R., Trebst, C., & Stangel, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.008 · Cited by 202
Oligodendrocyte death results in immune-mediated CNS demyelination
Traka, M., Podojil, J. R., McCarthy, D. P., Miller, S. D., & Popko, B. (2016) · Nature Neuroscience · doi:10.1038/nn.4193 · Cited by 195
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
Brink, B. P., Veerhuis, R., Breij, E. C. W., van der Valk, P., Dijkstra, C. D., & Bö, L. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.147 · Cited by 191
The blood-brain barrier in cortical multiple sclerosis lesions
van Horssen, J., Brink, B. P., de Vries, H. E., van der Valk, P., & Bø, L. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318040b2de · Cited by 187
The role of microglia in multiple sclerosis
Luo, C., Jian, C., Liao, Y., Huang, Q., Wu, Y., Liu, X., Zou, D., & Wu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s140634 · Cited by 187
Steelman, A. J., Thompson, J. P., & Li, J. (2012) · Neuroscience Research · doi:10.1016/j.neures.2011.10.002 · Cited by 183
The complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration
Alexander, J. J., Anderson, A. J., Barnum, S. R., Stevens, B., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05668.x · Cited by 177
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176
LDL Receptor–Related Protein-1
Gonias, S. L., & Campana, W. M. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.029 · Cited by 175
Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions
Gaitán, M. I., Shea, C. D., Evangelou, I. E., Stone, R. D., Fenton, K. M., Bielekova, B., Massacesi, L., & Reich, D. S. (2011) · Annals of Neurology · doi:10.1002/ana.22472 · Cited by 174
“Many studies (but not all) suggest that the pathogenic processes involved in the onset and enlargement of MS plaques start from lymphomonocytic infiltrates surrounding that vein.(3,4) There is also perivascular inflammation around small blood vessels at the edges of expanding lesions and in the normal-appearing white…”
Backgroundvan Horssen, J., Singh, S., van der Pol, S., Kipp, M., Lim, J. L., Peferoen, L., Gerritsen, W., Kooi, E.-J., Witte, M. E., Geurts, J. J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-156 · Cited by 172
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
A Comparison of 3T and 7T in the Detection of Small Parenchymal Veins Within MS Lesions
Tallantyre, E. C., Morgan, P. S., Dixon, J. E., Al-Radaideh, A., Brookes, M. J., Evangelou, N., & Morris, P. G. (2009) · Investigative Radiology · doi:10.1097/rli.0b013e3181b4c144 · Cited by 164
“On the other hand, other authors suggest that such histologic heterogeneity simply reflects the different age of lesions - central veins being consistently absent in very early lesions and consistently present in chronic lesions.(10,11) Longitudinal 7T T2* imaging could be a useful tool in resolving this uncertainty r…”
BackgroundThe translational biology of remyelination: past, present, and future
Franklin, R. J. M., & Gallo, V. (2014) · Glia · doi:10.1002/glia.22622 · Cited by 162
Clarner, T., Diederichs, F., Berger, K., Denecke, B., Gan, L., van der Valk, P., Beyer, C., Amor, S., & Kipp, M. (2012) · Glia · doi:10.1002/glia.22367 · Cited by 155
CXCL10 Triggers Early Microglial Activation in the Cuprizone Model
Clarner, T., Janssen, K., Nellessen, L., Stangel, M., Skripuletz, T., Krauspe, B., Hess, F.-M., Denecke, B., Beutner, C., Linnartz-Gerlach, B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401459 · Cited by 150
Oligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Self-citationPohl, H. B. F., Porcheri, C., Mueggler, T., Bachmann, L. C., Martino, G., Riethmacher, D., Franklin, R. J. M., Rudin, M., & Suter, U. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5035-10.2011 · Cited by 145
Binder, M. D., Cate, H. S., Prieto, A. L., Kemper, D., Butzkueven, H., Gresle, M. M., Cipriani, T., Jokubaitis, V. G., Carmeliet, P., & Kilpatrick, T. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1180-08.2008 · Cited by 138
“Oligodendrocyte damage and death are common elements of CNS demyelination (Barnett and Prineas, 2004).”
BackgroundInfluentialBuschmann, J. P., Berger, K., Awad, H., Clarner, T., Beyer, C., & Kipp, M. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9773-x · Cited by 133
Versijpt, J., Debruyne, J. C., Van Laere, K. J., De Vos, F., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1140oa · Cited by 126
Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus
Norkute, A., Hieble, A., Braun, A., Johann, S., Clarner, T., Baumgartner, W., Beyer, C., & Kipp, M. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21946 · Cited by 123
Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis
Gaultier, A., Wu, X., Le Moan, N., Takimoto, S., Mukandala, G., Akassoglou, K., Campana, W. M., & Gonias, S. L. (2009) · Journal of Cell Science · doi:10.1242/jcs.040717 · Cited by 118
The immunomodulatory oligodendrocyte
Zeis, T., Enz, L., & Schaeren-Wiemers, N. (2016) · Brain Research · doi:10.1016/j.brainres.2015.09.021 · Cited by 120
Groebe, A., Clarner, T., Baumgartner, W., Dang, J., Beyer, C., & Kipp, M. (2009) · The Cerebellum · doi:10.1007/s12311-009-0099-3 · Cited by 116
“Interestingly, Barnett et al. [ 42 ] recently presented data concerning the pathology of the newly forming lesion.”
BackgroundImaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
The formation of inflammatory demyelinated lesions in cerebral white matter
Maggi, P., Macri, S. M. C., Gaitán, M. I., Leibovitch, E., Wholer, J. E., Knight, H. L., Ellis, M., Wu, T., Silva, A. C., Massacesi, L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24242 · Cited by 110
Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death
Veto, S., Acs, P., Bauer, J., Lassmann, H., Berente, Z., Setalo, G., Borgulya, G., Sumegi, B., Komoly, S., Gallyas, F., et al. (2010) · Brain · doi:10.1093/brain/awp337 · Cited by 107
Biochemically altered myelin triggers autoimmune demyelination
Caprariello, A. V., Rogers, J. A., Morgan, M. L., Hoghooghi, V., Plemel, J. R., Koebel, A., Tsutsui, S., Dunn, J. F., Kotra, L. P., Ousman, S. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721115115 · Cited by 104
In toxic demyelination oligodendroglial cell death occurs early and is FAS independent
Hesse, A., Wagner, M., Held, J., Brück, W., Salinas-Riester, G., Hao, Z., Waisman, A., & Kuhlmann, T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.016 · Cited by 98
Plemel, J. R., Caprariello, A. V., Keough, M. B., Henry, T. J., Tsutsui, S., Chu, T. H., Schenk, G. J., Klaver, R., Yong, V. W., & Stys, P. K. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201602028 · Cited by 97
Metadata
- Authors
- Barnett, M. H., & Prineas, J. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-03-21
- Volume
- 55
- Issue
- 4
- Pages
- 458-468
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1987057401
- Cited by
- 1,185
- References
- 62
- FWCI
- 56.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.